Naptumomab estafenatox
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Schematic image of naptumomab estafenatox. VH, VL: variable (antigen binding) domains of antibody fragment | |
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | 5T4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C3255H5025N855O1050S18 |
| Molar mass | 73513.02 g·mol−1 |
  (what is this?) (verify) | |
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.[4]
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
